Compare PGEN & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | REAL |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.9B |
| IPO Year | 2013 | 2019 |
| Metric | PGEN | REAL |
|---|---|---|
| Price | $4.10 | $10.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $8.33 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 5.2M | 3.0M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.55 |
| EPS | N/A | ★ N/A |
| Revenue | $230,981,000.00 | ★ $692,845,000.00 |
| Revenue This Year | $1,115.92 | $14.30 |
| Revenue Next Year | $81.04 | $10.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.38 |
| 52 Week Low | $1.23 | $4.71 |
| 52 Week High | $5.47 | $17.39 |
| Indicator | PGEN | REAL |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 51.93 |
| Support Level | $4.02 | $9.61 |
| Resistance Level | $4.44 | $11.48 |
| Average True Range (ATR) | 0.32 | 0.52 |
| MACD | 0.12 | 0.23 |
| Stochastic Oscillator | 83.08 | 84.90 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.